272


Alyssa B. Christensen et al


Fig. 2. HO-CDI incidence rates before and after implementation of ASP clinical review of NAAT. HO-CDI incidence rate per 10,000 patient days observed and predicted mean fits displayed (Y-axis). Transformed coefficients from Poisson regression were used to generate incident rate predictions per 10,000 patient days. Time was modeled as increasing months from 1 to 52 with Intervention as a binary classifier. Note. Light grey shading: provider education disseminated. Dark grey shading: ASP driven preauthorization paired with education. ASP, antimicrobial stew- ardship; CDI, Clostridioides difficile infection; HO, hospital-onset.


Fig. 3. Facility-wide CDI SIR before and after implementation of ASP clinical review of NAAT. HO-CDI SIR observed and predicted mean fits displayed (Y-axis). Transformed model coeffi- cients from Gamma log-linked regression were used to generate CDI SIR predictions. Time was modeled as increasing months from 1–52 with intervention as a binary classifier. Note. Light grey shading: provider education dissemi- nated. Dark grey shading: ASP driven pre- authorization paired with education. ASP, antimi- crobial stewardship; CDI, Clostridioides difficile infection; SIR, standardized infection ratio.


Oral vancomycin before and after prospective ASP review, 2014−2018 Y = exp[−4.76 + 0.984 (Intervention) + 0.013 (Time) − 0.031 (Time X Intervention)]


mean consumption, before and after ASP predicted consumption, without ASP


Fig. 4. Facility-wide oral vancomycin before and after implementation of ASP clinical review of NAAT. Oral vancomycin consumption (AD) per 1,000 days present (DP) observed and predicted mean fits displayed (Y-axis). Transformed coeffi- cients fromPoisson regression were used to gen- erate consumption rate predictions per 1,000 patient days. Time was modeled as increasing months from 1–52 with Intervention as a binary classifier. Note. Light grey shading: provider edu- cation disseminated. Dark grey shading: ASP driven pre-authorization paired with education. AD, antimicrobial days; ASP, antimicrobial stew- ardship; PO, orally administered.


2014


2015 Year


2016


2017


2018


05 10


Oral vancomycin AD per 1000 DP 15


20


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132